,113 MSH2 and MLH1 are unlikely to be good therapeutic targets in the CNS as their loss is associated with significantly increased risk of CNS cancers, as is the loss of PMS2 to a lesser degree.114. This evidence concerns the gene MLH1 and central nervous system cancer.